From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
1P-LSD Structural Formulae V.1.svg
Legal status
Legal status
CAS Number
  • none
PubChem CID
Chemical and physical data
Formula C23H29N3O2
Molar mass 379.50 g·mol−1
3D model (JSmol)

1P-LSD or 1-propionyl-lysergic acid diethylamide is a psychedelic drug of the lysergamide class that is a derivative and functional analog of LSD and a homolog of ALD-52. It has been sold online as a designer drug since 2015.[1][2][3][4][5][6]


While 1P-LSD shows only 38% the potency of LSD in mice, LSD is detected via LC-MS when 1P-LSD is incubated in human serum.[7] This implies that 1P-LSD acts as a prodrug for LSD. This partially explains the effects of 1P-LSD, because the compound itself is unable to bind to the 5-HT2A receptors responsible for the effects of psychedelic drugs.[8][9]

Prior to the publishing of the above cited research, pharmacologist David E. Nichols reportedly commented with his thoughts on 1P-LSD serotonin receptor binding:[10]


The effects profile of 1P-LSD is not well defined. It is generally thought to be comparable to that of LSD.[11]

Legal status[edit]


1P-LSD is not scheduled by the United Nations' Convention on Psychotropic Substances.[12]


1P-LSD is illegal in Belgium since 26 September 2017.[13]


1P-LSD is illegal in Denmark.[14]


1p-LSD is illegal in Finland.[citation needed]


1P-LSD is not regulated by law in Germany.[citation needed]


1P-LSD is illegal in Japan since 18 April 2016.[15]


1P-LSD is illegal in Latvia. Although it isn't specifically scheduled, it is controlled as an LSD structural analog due to an amendment made on June 1, 2015.[16]


1p-LSD is illegal in Lithuania.[citation needed]


1P-LSD is illegal in Norway.[17]


1P-LSD is legal in Poland.[citation needed]


Public Health Agency of Sweden added 1p-LSD as health hazard under the act Act on the Prohibition of Certain Goods Dangerous to Health (SFS 1999:42) in Sweden as of January 26, 2016, published in SFS 2015:997 listed as N,N-dietyl-6-metyl-1-propionyl-9,10-didehydroergolin-8-karboxamid (1p-LSD).[18]


1P-LSD is illegal in Switzerland.[19]

United Kingdom[edit]

1P-LSD is illegal in the UK under the Psychoactive Substances Act.[citation needed]

United States[edit]

While 1P-LSD is not controlled at the federal level in the United States, it's possible that 1P-LSD could be considered as an analog of LSD, in which case trade or possession with intent for human consumption could be prosecuted under the Federal Analogue Act.[20]

See also[edit]


  1. ^ "Philtre Bulletin Issue 5" (PDF). WEDINOS. March 2015. Retrieved 28 July 2015. 
  2. ^ Max Daly (27 July 2015). "Why Young Brits Are Taking So Much LSD and Ecstasy". Vice. Retrieved 11 August 2015. 
  3. ^ "Newer Unregulated Drugs" (PDF). KFx. April 2015. Retrieved 13 August 2015. 
  4. ^ Matthew Speiser (11 August 2015). "A handful of dangerous new legal drugs has public health experts worried". Business Insider UK. Retrieved 13 August 2015. 
  5. ^ "1P-LSD". New Synthetic Drugs Database. 
  6. ^ Joseph J. Palamar; Patricia Acosta; Scott Sherman; Danielle C. Ompad; Charles M. Cleland (June 2016). "Self-reported use of novel psychoactive substances among attendees of electronic dance music venues". The American Journal of Drug and Alcohol Abuse: 1–9. doi:10.1080/00952990.2016.1181179. PMID 27315522. 
  7. ^ Simon D. Brandt; Pierce V. Kavanagh; Folker Westphal; Alexander Stratford; Simon P. Elliott; Khoa Hoang; Jason Wallach; Adam L. Halberstadt (October 2015). "Return of the lysergamides. Part I: Analytical and behavioural characterization of 1-propionyl-d-lysergic acid diethylamide (1P-LSD)". Drug Testing and Analysis. doi:10.1002/dta.1884. PMID 26456305. 
  8. ^ Jose (15 October 2015). "Is 1P-LSD A Prodrug To LSD?". Detect-Kit. Retrieved 15 October 2015. 
  9. ^ P. Linda; A. Stener; A. Cipiciani; G. Savelli (January–February 1983). "Hydrolysis of amides. Kinetics and mechanism of the basic hydrolysis of N-acylpyrroles, N-acylindoles and N-acylcarbazoles". Journal of Heterocyclic Chemistry. 20 (1): 247–248. doi:10.1002/jhet.5570200154. 
  10. ^ kman1898 (16 February 2015). "The Big & Dandy 1P-LSD Thread, Volume 1". Bluelight. 
  11. ^ Fabrizio Schifano; Laura Orsolini; Duccio Papanti; John Corkery (June 2016). "NPS: Medical Consequences Associated with Their Intake". Current Topics in Behavioral Neurosciences. Springer International Publishing. pp. 1–30. doi:10.1007/7854_2016_15. ISSN 1866-3370. OCLC 643052237. PMID 27272067. 
  12. ^ "International Drug Control Conventions". United Nations Office on Drugs and Crime (UNODC). 
  13. ^ "Royal decision regarding regulation of sedative substances, psychotropic substances" (PDF). Federal Agency for Medicines and Health Products. 26 September 2017. 
  14. ^ "Lists of euphoriant substances". The Danish Medicines Agency. September 2015. 
  15. ^ "指定薬物一覧" (PDF) (in Japanese). Ministry of Health, Labour and Welfare. 
  16. ^ "Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem" (in Latvian). Latvijas Republikas tiesību akti. 
  17. ^ "31 Forskrift om narkotika (narkotikaforskriften)" (in Norwegian). Helse- og omsorgsdepartementet. 14 February 2013. 
  18. ^ https://notisum.se/rnp/sls/sfs/20150997.pdf
  19. ^ "Verordnung des EDI über die Verzeichnisse der Betäubungsmittel, psychotropen Stoffe, Vorläuferstoffe und Hilfschemikalien" (in German). Der Bundesrat. 
  20. ^ "Introduction to the Federal Controlled Substance Analogue Act". Erowid. January 2001.